EDTA gel root conditioning: lack of effect on clinical and radiographic outcomes of intrabony defect treatment with enamel matrix derivative.
BACKGROUND
The adjunctive use of enamel matrix derivative (EMD) in the surgical therapy of intrabony defects results in improved outcomes compared to surgical debridement alone. However, the role of EDTA root conditioning in EMD therapy has not been investigated. The purpose of this study was to compare the 12-month outcomes of EMD application with and without EDTA root conditioning in intrabony defect surgical therapy.


METHODS
Twenty-eight chronic periodontitis patients, each contributing a 2- or 3-wall intrabony defect (> or = 4 mm deep and > or = 2 mm wide), participated. Patients consecutively received surgical treatment with either EMD alone (first 13 patients) or EMD + EDTA (subsequent 15 patients). Probing depth (PD), clinical attachment level (CAL), and gingival margin position, i.e., recession (REC) were the clinical parameters recorded. Recorded radiographic parameters were the distances from 1) cemento-enamel junction to bone crest (CEJ to BC), 2) CEJ to base of the defect (CEJ to BD), and 3) BC to BD.


RESULTS
Intragroup analysis showed that both EMD alone and EMD + EDTA led to significant PD reduction, CAL gain, and REC increase 1 year postoperatively. Both groups had >60% mean radiographic defect resolution (change in BC to BD). None of the recorded parameters were significantly different between the two groups, either at baseline or postoperatively.


CONCLUSIONS
These results suggest that clinical and radiographic outcomes of intrabony defect EMD therapy do not depend on the use of EDTA gel root conditioning. The potential contribution of EDTA gel root conditioning to the histological outcomes reported with EMD therapy remains to be determined.
Parashis
Andreas O
AO
Department of Oral Radiology, University of Athens, Athens, Greece.
Tsiklakis
Konstantinos
K
Tatakis
Dimitris N
DN
D000134:Acid Etching, Dental; D016301:Alveolar Bone Loss / Q000000981:diagnostic imaging / Q000473:pathology / Q000601:surgery*; D000539:Alveolar Process / Q000000981:diagnostic imaging / Q000473:pathology; D002614:Chelating Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002908:Chronic Disease; D003746:Dental Enamel Proteins / Q000627:therapeutic use*; D004492:Edetic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D005500:Follow-Up Studies; D005782:Gels; D005889:Gingival Recession / Q000601:surgery; D016557:Guided Tissue Regeneration, Periodontal; D006801:Humans; D017622:Periodontal Attachment Loss / Q000601:surgery; D010514:Periodontal Pocket / Q000601:surgery; D010518:Periodontitis / Q000601:surgery; D011859:Radiography; D019237:Tooth Cervix / Q000473:pathology; D014092:Tooth Root / Q000187:drug effects*; D016896:Treatment Outcome
D002614:Chelating Agents; D003746:Dental Enamel Proteins; D005782:Gels; C109069:enamel matrix proteins; D004492:Edetic Acid